Compositions and processes for targeted delivery, expression and modulation of coding ribonucleic acids in tissue
Compositions for expressing a polypeptide within a target organ, the composition comprising a delivery particle, and at least a first mRNA sequence complexed with, encapsulated by, or otherwise associated with the delivery particle, wherein the mRNA sequence comprises at least one coding sequence which codes for at least one polypeptide, at least a first untranslated region (UTR) sequence, and at least one micro-RNA (miRNA) binding site sequence, wherein the miRNA binding site sequence is located within, immediately 5′ to, or immediately 3′ to, the first UTR sequence; and wherein the miRNA binding site sequence provides for differential expression of the coding sequence between first and second cell types comprised within the target organ.
1. An isolated mRNA sequence comprising:
at least one coding sequence which codes for the at least one polypeptide, wherein said polypeptide is an oncolytic virus gene product involved in viral genome replication, or a mammalian cellular equivalent or homologue thereof;
at least a first untranslated region (UTR) sequence;
at least three substantially different micro-RNA (miRNA) binding site sequences, wherein at least two of the at least three miRNA binding site sequences are configured to bind miRNAs differentially expressed within different cell types comprised within a target organ of a subject, wherein the organ is liver; and
wherein the at least three substantially different miRNA binding site sequences are located within the first UTR sequence.
2. The isolated mRNA sequence of claim 1 , wherein the mRNA sequence comprises greater than three miRNA binding site sequences.
3. The isolated mRNA sequence of claim 1 , wherein the different cell types comprised within the liver of the subject are selected from the group consisting of: non-neoplastic cells; a transformed cell phenotype; a pre-cancerous phenotype; and a neoplastic phenotype.
4. The isolated mRNA sequence of claim 3 , wherein the liver cell type is a pre-cancerous or neoplastic cell type.
5. The isolated mRNA sequence of claim 4 , wherein the liver cell type is a liver cancer selected from a primary cancer or secondary/metastatic cancer in the liver.
6. The isolated mRNA sequence of claim 5 , wherein the liver cancer is a cholangiocarcinoma; angiosarcoma, hepatocarcinoma or hepatoblastoma.
7. The isolated mRNA sequence of claim 1 , wherein the mRNA comprises a further coding sequence that encodes a therapeutic enhancement factor.
8. The isolated mRNA sequence of claim 7 , wherein the therapeutic enhancement factor is selected from the group consisting of a tumor suppressor protein, a programmed cell death protein, an inhibitor of a programmed cell death pathway, a monoclonal antibody or fragment or derivative thereof, a sequence-specific nuclease, an oncolytic virus gene product, a cytokine, a chemokine, a fluorescent marker protein, an immunomodulatory molecule and combinations thereof.
9. The isolated mRNA sequence of claim 1 , wherein the at least three substantially different miRNA binding site sequences hybridize with an miRNA selected from the group consisting of miRNA-122; miRNA-124a; miRNA-125; Let-7; and miRNA-375.
10. The isolated mRNA sequence of claim 1 , wherein the oncolytic virus gene product is a viral gene product of an oncolytic virus selected from of the Groups I viruses of the Baltimore classification of viruses or mammalian equivalent or homologue thereof.
11. The isolated mRNA sequence of claim 1 , wherein the oncolytic virus gene product is a ribonucleotide reductase.
12. The isolated mRNA sequence of claim 1 , wherein the mRNA comprises a further coding sequence.
13. A pharmaceutical composition comprising:
at least one mRNA sequence comprising:
at least one coding sequence which codes for at least one polypeptide, wherein said polypeptide is an oncolytic virus gene product involved in viral genome replication, or a mammalian cellular equivalent or homologue thereof;
at least a first untranslated region (UTR) sequence;
at least three substantially different micro-RNA (miRNA) binding site sequences, wherein at least two of the at least three miRNA binding site sequences are configured to bind miRNAs differentially expressed within different cell types comprised within a target organ of a subject, wherein the organ is liver;
wherein the at least three substantially different miRNA binding site sequences are located within the first UTR sequence;
and
a pharmaceutically acceptable carrier.
14. The isolated mRNA sequence of claim 1 , or the pharmaceutical composition of claim 13 , wherein the oncolytic virus is selected from the group consisting of Vesicular Stomatitis Virus, Maraba virus, Polio virus, Reovirus, Measles virus, Newcastle disease virus, Coxsackievirus A21, Parvovirus, Herpes Simplex Virus Type 1, and Adenovirus.
15. The pharmaceutical composition of claim 13 , wherein the oncolytic virus gene product is a ribonucleotide reductase.
16. The pharmaceutical composition of claim 13 , wherein the isolated mRNA sequence is encapsulated in a delivery particle.
17. The pharmaceutical composition of claim 13 , wherein the delivery particles comprises aminoalcohol lipidoids.
18. The pharmaceutical composition of claim 13 , further comprise one or more targeting agents selected from the group consisting of proteins, peptides, carbohydrates, glycoproteins, lipids, small molecules and nucleic acids.
19. The pharmaceutical composition of claim 13 , wherein the liver cell type is a pre-cancerous or neoplastic cell type.
20. The pharmaceutical composition of claim 13 , wherein the liver cell type is a liver cancer selected from a primary cancer or secondary/metastatic cancer in the liver.
21. The pharmaceutical composition of claim 13 , wherein the liver cancer is a cholangiocarcinoma; angiosarcoma, hepatocarcinoma or hepatoblastoma.
22. The pharmaceutical composition of claim 13 , wherein the composition is formulated for intrahepatic delivery.